Kevin Norrett compensation by year
SOLENO THERAPEUTICS Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $59,275 |
| Bonus | $0 |
| Stock awards | $675,014 |
| Option awards | $2,633,797 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $150 |
| Total | $3,369,336 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SOLENO THERAPEUTICS INC 10-K/A filed April 30, 2026, accession 0001193125-26-197594, and prior-year filings. Open the filing on EDGAR.
How this page was built: the SOLENO THERAPEUTICS INC filed document, accession 0001193125-26-197594. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 14,286 | $661,442 | — |
| Option | 64,286 | — | $47.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in SOLENO THERAPEUTICS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-18 | Disposition to the issuer | — | 17,786 | — | 0 |
| 2026-05-18 | Disposition to the issuer derivative | — | 64,286 | — | 0 |
| 2026-05-18 | Disposition to the issuer derivative | — | 4,000 | — | 0 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
SOLENO THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Anish Bhatnagar | CEO and Chairman of the Board | $8,872,611 |
| Manher Joshi | Chief Development Officer | $3,721,576 |
| Kevin Norrett · this page | Chief Business Officer | $3,369,336 |
| James Mackaness | Former Chief Financial Officer | $2,786,453 |
| Meredith Manning | Chief Commercial Officer | $2,606,156 |
The full SOLENO THERAPEUTICS compensation record
free company briefThis page is one person within SOLENO THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the SOLENO THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SOLENO THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.